Aged patients with metastatic castration resistant prostate cancer: Should we treat with chemotherapy?

Related Articles

Aged patients with metastatic castration resistant prostate cancer: Should we treat with chemotherapy?

Cancer Treat Rev. 2017 Apr 03;55:173-180

Authors: Climent MÁ, Torregrosa MD, Vázquez S, Gironés R, Arranz JA

Abstract
Prostate cancer largely affects aged men and as life expectancy continues to increase, it is likely to be a growing burden requiring an adequate management. Aging is a heterogeneous process, thus, to assess the individual state of health when making decisions is essential. Comprehensive geriatric assessment allows a detailed evaluation of the state of health of a specific subject and can modify the therapeutic decision. It is still not commonly used because it is time consuming. Chemotherapy should be administered equally in aged well-fit patients as in the general population as per the SIOG (International society of geriatric oncology) recommendations for geriatric evaluation and treatment in prostate cancer patients. Chemotherapy with docetaxel or cabazitaxel is expected to have an efficacy and toxicity similar to younger patients and they might be considered treatment options for these patients among others. In vulnerable or frail patients, weekly or biweekly docetaxel regimens are acceptable treatment options.

PMID: 28411479 [PubMed - as supplied by publisher]

http://ift.tt/2plEudG